Compounds > b 807-27
Page last updated: 2024-11-13

b 807-27

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23676477
CHEMBL ID14341
SCHEMBL ID1580449
MeSH IDM0107782

Synonyms (15)

Synonym
oxiranecarboxylic acid, 2-(5-(4-chlorophenyl)pentyl)-, sodium salt
2-(5-(p-chlorophenyl)pentyl)glycidic acid sodium salt
sodium 2-(5-(4-chlorophenyl)pentyl)oxirane-2-carboxylate
b 807-27
glycidic acid, 2-(5-(p-chlorophenyl)pentyl)-, sodium salt
oxirane-2-carboxylic acid, 2-(5-(p-chlorophenyl)pentyl)-, sodium salt
CHEMBL14341
rac-clomoxir sodium
78573-70-3
sodium 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate
VMVZSXFXGNJMPW-UHFFFAOYSA-M
SCHEMBL1580449
sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate
DTXSID00999849
sodium;2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID719774Reduction in blood glucose in po dosed Sprague-Dawley rat2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719762Reduction in total cholesterol level in fasted Sprague-Dawley rat at 8 to 300 umol/kg, po measured 24 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719768Inhibition of CPT1 in fasted Sprague-Dawley rat liver mitochondria at 0.6 to 60 umol/kg, po measured 4 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719773Toxicity in po dosed Sprague-Dawley rat assessed as hypoglycemic coma2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719799Reduction in oxidation rate in rat liver mitochondria treated at 0.05% or 0.2% dose through food-admix for 12 weeks by polarographic oxygen uptake method2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719671Inhibition of rat FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719763Increase in plasma TG level in fasted Sprague-Dawley rat at 8 to 300 umol/kg, po measured 2 to 4 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719672Cytotoxicity in human KB cells2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID176120Ability to decrease blood glucose levels in fasted rats at the dose of 0.6 mmol/kg was determined1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
AID719801Inhibition of carnitine palmitoyltransferase in hepatocytes from fasted rat assessed as oxidation of [U-14C]palmitate and production of acetoacetate and BHB2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID177862Effective dose at which 50% of the rats show at least a 25% decrease of blood glucose levels compared to controls1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
AID719673Inhibition of human FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719765Reduction in blood KB level in fasted Sprague-Dawley rat at 8 to 300 umol/kg, po2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719769Reduction in blood KB in fasted Sprague-Dawley rat at 0.6 to 60 umol/kg, po2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719802Inhibition of carnitine palmitoyltransferase in human fibroblasts assessed as [14]CO2 production from [U-14C]glucose at 5 to 50 uM by radiometric assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719767Reduction in blood glucose in fasted Sprague-Dawley rat at 8 to 300 umol/kg, po measured 2 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID70216Tested for its effect on hepatic epoxide hydrolase; No significant inhibition up to 1e-3 mol/L1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
AID719766Reduction in blood glucose in po dosed fasted Sprague-Dawley rat2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID116917Compound was tested for its lethality in mice when administered perorally1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
AID719760Reduction in blood glucose in SPF-white inbred guinea pig at 7 to 56 umol/kg, po2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719805Increase in coronary flow in perfused rat heart at 5 mg/kg, sc administered as single dose administered 120 mins before start of perfusion2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719803Inhibition of carnitine palmitoyltransferase in human fibroblasts assessed as [14]CO2 production from [1-14C]pyruvate at 5 to 50 uM by radiometric assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719771Reduction in glucose AUC in db/db mouse at 19 umol/kg/day, po for 4 days administering last dose 1 hr before glucose load by OGTT test2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719772Reduction in FBG in db/db mouse at 19 umol/kg/day, po for 4 days measured 1 hr post dose after 16 hrs fasting2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719784Inhibition of CPT1 in Sprague-Dawley rat liver mitochondria at 0.6 to 60 umol/kg, po measured 4 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719770Reduction in blood glucose in fasted Sprague-Dawley rat at 0.6 to 60 umol/kg, po2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719800Reduction in oxidation rate in rat liver mitochondria treated at 0.05% or 0.2% dose through food-admix for 12 weeks2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719761Reduction in blood glucose in adrenalectomized rat at 25 to 150 umol/kg, po2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719764Increase in plasma FFAs level in fasted Sprague-Dawley rat at 8 to 300 umol/kg, po measured 2 to 4 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719775Reduction in blood glucose in Sprague-Dawley rat at 600 umol/kg, po2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719785Reduction in blood KB in Sprague-Dawley rat at 0.6 to 60 umol/kg, po2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719804Inhibition of carnitine palmitoyltransferase in human fibroblasts assessed as [14]CO2 production at 5 to 50 uM from [U-14C]palmitate by radiometric assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719630Reduction in blood glucose in STZ-treated diabetic pig at 10 to 40 umol/kg, iv measured 6 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (63.64)18.7374
1990's3 (27.27)18.2507
2000's0 (0.00)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carnitine
[no description available]		1.9710amino-acid betainehuman metabolite;
mouse metabolite
4-hydroxyphenylglyoxylic acid
4-hydroxyphenylglyoxylic acid: RN given refers to parent cpd. 4-hydroxyphenylglyoxylate : Conjugate base of 4-hydroxyphenylglyoxylic acid.		2.0610phenols
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		1.96102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
palmitic acid
Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.		1.9710long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
pyruvic acid
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.		1.96102-oxo monocarboxylic acidcofactor;
fundamental metabolite
2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid
[no description available]		2.420
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		2.06101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
ciprofibrate
[no description available]		1.9710cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		1.9710aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clofibric acid
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.		1.9710aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
perhexiline
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.		2.0610piperidinescardiovascular drug
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		1.9710organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
potassium cyanide
[no description available]		1.9710cyanide salt;
one-carbon compound;
potassium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
neurotoxin
hexacosanoic acid
hexacosanoic acid: a C(26) saturated acid. hexacosanoic acid : A 26-carbon, straight-chain, saturated fatty acid.		1.9710fatty acid 26:0;
straight-chain saturated fatty acid;
very long-chain fatty acid
trimetazidine
Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease.		2.0610aromatic amine
4-hydroxyphenylglycine, (s)-isomer
L-4-hydroxyphenylglycine : The L-enantiomer of 4-hydroxyphenylglycine.		2.06104-hydroxyphenylglycine
bezafibrate
[no description available]		1.9710aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate
[no description available]		2.8940
methyl 2-tetradecylglycidate
methyl 2-tetradecylglycidate: structure		2.0610
emeriamine
emeriamine: derived from fungal metabolite emericedin; structure given in first source		2.0610
oleic acid
Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.		1.9610octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
antimycin a
Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.		1.9710amidobenzoic acid
etomoxir
[no description available]		2.4120aromatic ether
4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate
[no description available]		2.0610
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid: an anorectic fatty acid synthase inhibitor; structure in first source. (2R,3S)-C75 : A 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid that has 2R,3S-configuration.		2.06104-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid;
gamma-lactone
antimycin
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetes Mellitus, Adult-Onset
[description not available]		02.0610
Cardiac Failure
[description not available]		02.0610
Insulin Sensitivity
[description not available]		02.0610
Heart Disease, Ischemic
[description not available]		02.0610
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.0610
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.0610
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.0610
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.0610
Alloxan Diabetes
[description not available]		02.3720
Coronary Heart Disease
[description not available]		01.9710
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.		01.9710